Ascendis Pharma A (ASND) EBT (2014 - 2026)

Ascendis Pharma A (ASND) has 13 years of EBT data on file, last reported at -$56.4 million in Q1 2026.

• For the quarter ending Q1 2026, EBT rose 42.69% year-over-year to -$56.4 million; the trailing twelve-month figure through Mar 2026 stood at -$194.2 million (up 46.61% YoY), and the FY2025 full-year result was -$247.5 million, up 38.72% from the prior year.
• EBT fell to -$56.4 million in Q1 2026, from -$31.1 million in the prior quarter.
• In the past five years, EBT ranged from a high of -$31.1 million in Q4 2025 to a low of -$206.2 million in Q4 2022.
• A 5-year average of -$106.8 million and a median of -$107.8 million in 2024 frame the typical range for EBT.
• Across the five-year window, EBT tumbled 85.04% in 2022 and jumped 66.29% in 2025, its largest moves.
• Tracing ASND's EBT over 5 years: stood at -$206.2 million in 2022, then soared by 57.68% to -$87.2 million in 2023, then surged by 54.21% to -$39.9 million in 2024, then advanced by 22.19% to -$31.1 million in 2025, then sank by 81.44% to -$56.4 million in 2026.
• Business Quant data shows ASND's EBT at -$56.4 million in Q1 2026, -$31.1 million in Q4 2025, and -$67.1 million in Q3 2025.